ADARx Pharmaceuticals, Inc. (ADRX) company profile
ADRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Last filing: 10-Q on Nov 12, 2026
$13.82−0.18 (-1.29%)
Close on Nov 17, 2026Market cap $1.48BP/E –Yield –
About ADARx Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
ADARx Pharmaceuticals, Inc. is listed on Nasdaq under the ticker ADRX, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31.
Company profile
Company
- Legal name
- ADARx Pharmaceuticals, Inc.
- Headquarters
- San Diego, CA
- Address
- 5871 Oberlin Drive, Suite 200 92121
- Phone
- (858) 283-9472
- Website
- adarx.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- ADRX
- Exchange
- Nasdaq
- IPO date
- Sep 28, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1802369
- CUSIP
- 00654F105
- ISIN
- US00654F1057
- FIGI
- BBG00WHNQV30
- Share class FIGI
- BBG00WHNQV49
- EIN
- 84-4145188
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Zhen Li | President and CEO, Director | 5,861,199 |
| Rui (NMN) Zhu | Chief Technology Officer | 2,511,943 |
| Ryan Fisk | CFO and CBO | – |
| Robert William Ackles | Chief People Officer | – |
| Alan Robert MacLeod | Chief Scientific Officer | – |
| Capital GP VII LLC OrbiMed | Director | – |
| Advisors Llc Orbimed | Director | – |
| Carl L. Gordon | Director | 7,127,019 |
| Advisors Israel II Ltd OrbiMed | Director | – |
| Erez Chimovits | Director | 8,974,061 |
| Genesis GP LLC OrbiMed | Director | 588,235 |
| OrbiMed Israel GP II, L.P. | Director | – |
| Simeon George | Director | 7,133,690 |
| Ying Huang | Director | – |
| Mary Tagliaferri | Director | – |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Sep 28, 2026
- Offer price
- $17.00
- Securities offered
- 26,250,000
- Gross proceeds
- $446.25M
- Exchange
- Nasdaq
- First trading day
- Sep 25, 2026
- First-day close
- $19.35+13.8%
- Lock-up ends (est.)
- Mar 24, 2027
“The initial public offering price is $17.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 28, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 22, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?